Venlo, The Netherlands, April 30, 2020 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has posted its Annual Report prepared in accordance with IFRS accounting standards for the year ended December 31, 2019 on its website. This report, which is only for statutory purposes, can be accessed on QIAGEN’s website at:... Read more
Venlo, the Netherlands, April 23, 2020 – QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the first quarter 2020 results on Wednesday, May 6, at approximately 22:05 Central European Time (CET) / 16:05 Eastern Day Time (EDT). Given the announced transaction with Thermo... Read more
Germantown, Maryland, and Hilden, Germany, April 15 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced launch of its novel therascreen® BRAF V600E RGQ PCR Kit (therascreen BRAF V600E Kit) following U.S. Food and Drug Administration (FDA) approval as a companion diagnostic to the BRAF inhibitor, BRAFTOVI® (encorafenib), which the FDA has... Read more
Venlo, The Netherlands, April 9, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales and adjusted earnings per share results for the first quarter of 2020. Net sales rose approximately 9% at constant exchange rates (CER) compared to the outlook for the first quarter announced on February 4, 2020, for... Read more
Germantown, Maryland, and Hilden, Germany, March 31, 2020 –QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test for use in diagnosing patients infected with the novel COVID-19 coronavirus. The QIAstat-Dx... Read more
Germantown, Maryland, and Hilden, Germany, March 24, 2020 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has begun shipments to the United States of its new QIAstat-Dx Respiratory SARS-CoV-2 Panel test to aid in diagnosing patients infected with the novel COVID-19 coronavirus under a new Policy of the U.S. Food and... Read more
Hilden, Germany, and Germantown, Maryland, March 17, 2020 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to dramatically ramp up global production capacity of RNA extraction kits that are used as part of workflows around the world to detect nucleic acid from SARS-CoV-2, the novel coronavirus that causes COVID-19. QIAGEN has historically... Read more
Hilden, Germany, and Germantown, Maryland, March 13, 2020 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will develop a new QIAstat-Dx test kit to differentiate the novel SARS-CoV-2 coronavirus from 21 other serious respiratory infections and will receive advanced development support from the U.S. Department of Health and Human Services’ Office of... Read more
WALTHAM, Mass. and VENLO, The Netherlands – March 3, 2020 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that their boards of directors, as well as the managing... Read more
Germantown, Maryland, and Hilden, Germany, March 2, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2019, with the U.S. Securities and Exchange Commission. The document can be accessed on... Read more